MX2013000760A - Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina. - Google Patents
Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina.Info
- Publication number
- MX2013000760A MX2013000760A MX2013000760A MX2013000760A MX2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A
- Authority
- MX
- Mexico
- Prior art keywords
- dopamine
- dopa
- agents
- individual
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36601510P | 2010-07-20 | 2010-07-20 | |
| PCT/GB2011/051376 WO2012010896A1 (en) | 2010-07-20 | 2011-07-20 | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013000760A true MX2013000760A (es) | 2013-10-28 |
Family
ID=44583771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000760A MX2013000760A (es) | 2010-07-20 | 2011-07-20 | Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130210786A1 (OSRAM) |
| EP (1) | EP2595621A1 (OSRAM) |
| JP (1) | JP2013543482A (OSRAM) |
| KR (1) | KR20130043197A (OSRAM) |
| CN (1) | CN103189056A (OSRAM) |
| AU (1) | AU2011281336B2 (OSRAM) |
| BR (1) | BR112013001422A2 (OSRAM) |
| CA (1) | CA2805693A1 (OSRAM) |
| EA (1) | EA201390070A1 (OSRAM) |
| MX (1) | MX2013000760A (OSRAM) |
| SG (1) | SG187090A1 (OSRAM) |
| WO (1) | WO2012010896A1 (OSRAM) |
| ZA (1) | ZA201301231B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20110244A7 (es) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
| WO2013183055A1 (en) | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| JP2017008044A (ja) * | 2015-06-22 | 2017-01-12 | 学校法人 久留米大学 | ドーパミンシグナル伝達の抑制剤 |
| CN105106230A (zh) * | 2015-08-16 | 2015-12-02 | 南京华宽信息咨询中心 | 一种单胺氧化酶mao抑制剂及其应用 |
| BR112022001595A2 (pt) | 2019-07-29 | 2022-03-22 | Peptron Inc | Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa |
| EP4037663A1 (en) | 2019-10-03 | 2022-08-10 | Starton Therapeutics, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US20230024384A1 (en) * | 2020-01-08 | 2023-01-26 | Neuroventi | Composition comprising lisuride compound for treating fragile x syndrome or related developmental disorders |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| CN115282156A (zh) * | 2022-09-05 | 2022-11-04 | 广东海洋大学 | 知母皂苷元在制备防治帕金森病的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA985172A (en) | 1972-10-06 | 1976-03-09 | Dushan M. Dvornik | Compositions and methods for reducing blood cholesterol |
| EP0102416A1 (en) | 1982-08-23 | 1984-03-14 | Nutrisearch Company | Blends of egg albumen and whey protein of improved gel strength |
| US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| JPH06502854A (ja) * | 1990-11-24 | 1994-03-31 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用 |
| DK1017379T3 (en) | 1997-03-17 | 2015-02-16 | Btg Int Ltd | Therapeutic compositions comprising ketone compounds and precursors thereof |
| CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| GB9905275D0 (en) | 1999-03-08 | 1999-04-28 | Phytopharm Ltd | Treatment of conditions associated with membrane-bound receptors and their function |
| EP1066033B1 (en) * | 1998-03-26 | 2005-12-28 | Phytopharm Plc | Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| DK1123094T3 (da) | 1998-09-15 | 2007-08-20 | Btg Int Ltd | Terapeutiske præparater (II) |
| GB2347676A (en) * | 1999-03-08 | 2000-09-13 | Phytopharm Plc | Screening method |
| GB9923078D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
| PL213697B1 (pl) * | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| JP4573157B2 (ja) * | 2002-03-27 | 2010-11-04 | フィトファーム・パブリック・リミテッド・カンパニー | 治療方法ならびにサポゲニンおよびその誘導体の使用 |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
| US20070041924A1 (en) * | 2005-08-19 | 2007-02-22 | Bioderm Research | Sebum Control Compositions Based on Saponins and Sapogenins |
| CA2750510A1 (en) * | 2009-01-24 | 2010-07-29 | Phytopharm Plc | Treatment of neurotrophic factor mediated disorders |
-
2011
- 2011-07-20 JP JP2013520218A patent/JP2013543482A/ja active Pending
- 2011-07-20 WO PCT/GB2011/051376 patent/WO2012010896A1/en not_active Ceased
- 2011-07-20 EA EA201390070A patent/EA201390070A1/ru unknown
- 2011-07-20 MX MX2013000760A patent/MX2013000760A/es not_active Application Discontinuation
- 2011-07-20 EP EP11738032.9A patent/EP2595621A1/en not_active Withdrawn
- 2011-07-20 KR KR1020137004015A patent/KR20130043197A/ko not_active Withdrawn
- 2011-07-20 CN CN2011800412824A patent/CN103189056A/zh active Pending
- 2011-07-20 CA CA2805693A patent/CA2805693A1/en not_active Abandoned
- 2011-07-20 SG SG2013003272A patent/SG187090A1/en unknown
- 2011-07-20 US US13/811,344 patent/US20130210786A1/en not_active Abandoned
- 2011-07-20 BR BR112013001422A patent/BR112013001422A2/pt not_active IP Right Cessation
- 2011-07-20 AU AU2011281336A patent/AU2011281336B2/en not_active Ceased
-
2013
- 2013-02-18 ZA ZA2013/01231A patent/ZA201301231B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG187090A1 (en) | 2013-02-28 |
| JP2013543482A (ja) | 2013-12-05 |
| CN103189056A (zh) | 2013-07-03 |
| EA201390070A1 (ru) | 2013-09-30 |
| US20130210786A1 (en) | 2013-08-15 |
| CA2805693A1 (en) | 2012-01-26 |
| KR20130043197A (ko) | 2013-04-29 |
| AU2011281336A1 (en) | 2013-01-31 |
| ZA201301231B (en) | 2014-04-30 |
| BR112013001422A2 (pt) | 2019-09-24 |
| EP2595621A1 (en) | 2013-05-29 |
| WO2012010896A1 (en) | 2012-01-26 |
| AU2011281336B2 (en) | 2015-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011281336B2 (en) | Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders | |
| MX2011007842A (es) | Tratamiento de trastornos mediados por factores neurotroficos. | |
| CN106692122A (zh) | 以5‑氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂 | |
| AU2002336765B2 (en) | Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder | |
| JP2023153871A (ja) | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 | |
| CN101657194A (zh) | 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法 | |
| WO2012113079A1 (en) | Cystamine analogues for the treatment of parkinson's disease | |
| Zhao et al. | Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract | |
| JP2022057307A (ja) | アンモニア代謝促進剤 | |
| WO2006043532A1 (ja) | パーキンソン病治療剤 | |
| WO2023164338A2 (en) | Compositions and methods for the treatment of sexual dysfunctions | |
| US20130017274A1 (en) | Low dose lithium in the treatment or prophylaxis of parkinson's disease | |
| EP0207011A2 (en) | Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism | |
| CN102355902A (zh) | 神经营养因子介导的病症的处理 | |
| CA3186900A1 (en) | Compositions and methods for treating psychiatric disorders or symptoms thereof | |
| EP1909782B1 (en) | Compositions comprising arginine and r-alpha-lipoic acid and their use for improvement of sexual function | |
| CN109562089A (zh) | 苯甲酸锂用于治疗中枢神经系统疾病的用途 | |
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| JP2009539941A (ja) | Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤 | |
| US20210275512A1 (en) | Pridopidine for treating drug induced dyskinesias | |
| McLean | Reviews of medical journal articles | |
| JP2024020094A (ja) | 低用量グルタチオンの肌の明度向上剤としての使用 | |
| JP2007511577A (ja) | （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用 | |
| Wolters | Conventional Pharmacotherapy in ParkinsonTs Disease | |
| TW200813038A (en) | Combination preparations comprising SLV308 and L-DOPA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |